Cargando…
Gut Microbiota and Response to Immunotherapeutic Drugs in Oncology: More Questions Than Answers
Immuno-oncology drugs (IODs) have revolutionized the treatment of some cancers. Although IODs are enabling some patients with cancer to become long-time survivors, only 30% to 40% respond to these drugs. There is experimental and clinical evidence that the gut microbiome may play a role in IOD respo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376376/ https://www.ncbi.nlm.nih.gov/pubmed/32742177 http://dx.doi.org/10.1177/1179554920933868 |